Who makes PARTICS using QVAR?

PARTICS using QVAR is developed by Brigham and Women's Hospital.

What development phase is PARTICS using QVAR in?

PARTICS using QVAR is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

PARTICS using QVAR

Brigham and Women's Hospital · FDA-approved active Small molecule Quality 0/100

PARTICS using QVAR is a marketed drug developed by Brigham and Women's Hospital, currently holding a position in the respiratory therapy segment. The key composition patent is set to expire in 2028, providing a clear period of exclusivity and potential revenue protection. The primary risk lies in the lack of disclosed primary trial results and competitors, which may impact the drug’s long-term market sustainability and competitive edge.

At a glance

Generic name	PARTICS using QVAR
Also known as	Patient Activated Reliever-Triggered Inhaled CorticoSteroid
Sponsor	Brigham and Women's Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations; PeRson EmPowered Asthma RElief (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results